ROS proto-oncogene 1 (ROS1) rearrangements, found in 1% to 2% of patients with non–small-cell lung cancer (NSCLC), can result in the expression of oncogenic fusion proteins in different tumor types.1 The gene discussed is ROS1; the disease is neoplasm.